Chemotherapy: Open Access
Open Access

Abstract

Broad Spectrum Anticancer Activity of Pistagremic Acid

Ghias Uddin, Abdur Rauf, Bina Shaheen Siddiqui, Ajmal Khan, Bishnu P Marasini, Abdul Latif and Thomas J Simpson

Background: Pistagremic acid; 3-methyl-7-(4,4,10,13,14-pentamethyl-3-2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthr-en-17-yl)-oct-3-enoic acid was isolated from the chloroform fraction of Pistacia integerrima. Cytotoxic evaluation against NCI-60 DTP human tumor cell line was performed. Methods: The anticancer assays for this compound were performed in accordance with the protocol of the Drug Evaluation Branch, by the National Cancer Institute (NCI) Developmental Therapeutic Program (www.dtp.nci.nih.gov) to be screened for their anticancer activity in vitro. Results: It showed broad spectrum antiproliferative activity with an average GI50, and TGI, values 0.103 μM and 0.259 μM, respectively. It also showed significant LC50 value at the average 0.634 μM against all cell lines excluding K-562, RPMI-8226, NCI-H226, and NCI-H460 cell-lines. Conclusions: Pistagremic acid showed cytotoxicity for all tested cancer cell line, thus it may serve as a potential structure lead for the development of new anticancer drugs.